MGX Metagenomi Therapeutics, Inc.

NASDAQ
$1.23

Metagenomi Therapeutics, Inc. (MGX) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.69 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.2% since its last earnings release on August 10, 2026.

Metagenomi Therapeutics Missed Consensus Estimates
Monday, August 10, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.69)
Rev est $1.25M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.22

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.

Sector

Healthcare

Industry

Biotechnology